AtriCure (ATRC) Cost of Revenue (2010 - 2026)

AtriCure (ATRC) has reported Cost of Revenue for 17 consecutive years, with $35.0 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Cost of Revenue rose 0.92% year-over-year to $35.0 million; the TTM figure through Jun 2026 stood at $135.0 million (up 6.79% YoY), while the FY2025 annual figure was $133.7 million, up 13.56% from the prior year.
• Cost of Revenue rose to $35.0 million in Q2 2026 per ATRC's latest filing, from $31.9 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $35.2 million in Q4 2025 and bottomed at $19.0 million in Q1 2022.
• Historically, Cost of Revenue has averaged $27.9 million across 5 years, with a median of $28.4 million in 2024.
• Annual changes were most pronounced in 2022 — Cost of Revenue increased 28.82% — and 2026, when it gained 0.92%.
• AtriCure's Cost of Revenue stood at $22.9 million in 2022, then rose by 16.64% to $26.7 million in 2023, then gained by 18.45% to $31.7 million in 2024, then gained by 11.07% to $35.2 million in 2025, then retreated by 0.53% to $35.0 million in 2026.
• Business Quant data shows ATRC's Cost of Revenue at $35.0 million in Q2 2026, $31.9 million in Q1 2026, and $35.2 million in Q4 2025.